Biopharma News

In their national budget announced by the UK Labour Party, biopharmaceutical production and manufacturing are set to receive a significant boost in capital grants through the Life Sciences Innovative Manufacturing Fund (LSIMF). 

In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024.  

The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. 

The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. 

On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin...

With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. 

In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. 

American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa. 

The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden...

In our latest CPHI Online Trend Report, we partner with Asymchem to understand the innovative potential of flow chemistry for API manufacturing, especially in regards to meeting sustainability goals. 

Recent data presented at the 2024 European Society for Cardiology (ESC) conference analysed Novo Nordisk’s Ozempic (semaglutide) and its effectiveness in the management of chronic kidney disease (CKD). This follows previous analysis on semaglutid...

In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences.  

In partnership with BioArctic AB, pharmaceutical company Eisai has been granted Marketing Authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA) for its Alzheimer’s disease drug product Leqembi. 

In our monthly series on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. 

Samsung Bioepis, the biologics unit of Samsung, has been issued a lawsuit brought forth by Amgen over proposed biosimilars of Amgen’s bone drugs Prolia and Xgeva. 

The MDMA-based therapeutic developed by Lykos Therapeutics, a California-based Public Benefit Corporation (PBC), has been reviewed and unapproved by the US FDA. The regulator has requested additional phase III trial data for further safety and efficacy...

Global pharmaceutical companies Novartis and Viatris are the latest hit with a lawsuit claim pertaining to alleged misuse of the ‘HeLa’ cell line from the estate of woman whose cancerous tissue cells were taken without consent. 

French pharmaceutical company Sanofi have announced an investment of EUR1.3 billion at their existing BioCampus site in Frankfurt am Main for the expansion of insulin production. 

A University of Alabama at Birmingham startup has gained FDA clearance for Investigational New Drug clinical trials for an oral Type 1 diabetes drug, a milestone for diabetes treatment. 

With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. 

The European Medicine’s Agency (EMA), the drug regulator for the EU, rejected Eisai and Biogen’s Alzheimer’s drug product Leqembi, citing the drug’s slowing of cognitive decline did not outweigh the risk of serious brain swellin...

Following from its purchase of Carmot Therapeutics, Roche have announced positive early-stage trial success for its second obesity drug candidate acquired from Carmot Therapeutics.  

A recent study published in Science Advances has identified a set of microproteins produced exclusively in liver tumours, which may provide a clear target for the development of a cancer vaccine. 

American pharmaceutical giant Pfizer have continued with a reworked version of their weight-loss pill danuglipron, progressing with a once-daily version of the pill. 

The latest CPHI Online Trend Report dives into what it really costs to develop, manufacture, and deploy pharmaceutical packaging that balances sustainability concerns, patient safety, and drug efficacy. 

After facing several hurdles on its path to approval last year, Eli Lilly’s donanemab treatment for early Alzheimer’s, brand name Kisunla, received US FDA approval this past week. It is the second therapy for slowing the progression of Alzh...

As drugmakers race to put their own GLP-1 drug products forward as the next biggest thing in weight-loss, current products are making numerous headlines this week with a number of new developments in their commercialisation and approval. Discover the l...

In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. 

Discover how a Chinese chemical manufacturing company went viral on TikTok, and what their viral success means for the future of B2B digital marketing for the wider pharmaceutical industry and supply chain.

Aurigene Pharmaceutical Services Ltd. have opened a biologics facility in Hyderabad, India in a biocluster known as Genome Valley.

Our Women in Pharma interview series is approaching its 1-year anniversary this month, and to celebrate, we are highlighting the Heroines of Pharma that our very own Women in Pharma admire.

Danish drugmaker Novo Nordisk have launched a new national campaign – The Power of Wegovy – that aims to educate those living with obesity on their blockbuster drug Wegovy throughout the United States.

Sanofi completed the acquisition of the clinical-stage biotech company Inhibrx in late May 2024 after settling on a US$1.7 billion buyout. The acquisition brings with it a rare disease therapy to bollster Sanofi's pipeline. 

Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. 

Pharmaceutical giant Sanofi have announced a collaboration with Formation Bio and OpenAI to build AI-powered software for accelerated drug development. 

In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. 

The British-Swedish drugmaker has announced plans to build a US$1.5 billion facility in Singapore for the manufacturing of antibody–drug conjugates (ADCs) to complement their existing cancer drug portfolio. 

Japanese drugmaker Eisai, in partnership with Biogen, have announced that they have begun submitting data on a rolling basis to the US FDA for a marketing application of a subcutaneous injectable form of Alzheimer’s drug Leqembi. 

A study from the USC Schaeffer Center for Health Policy & Economics has revealed the existence of racial disparities in the US for the diagnosis of dementia and the use of drug treatments for symptoms. 

American public benefit corporation (PBC) Lykos Therapeutics have announced that the US FDA Psychopharmacologic Drugs Advisory Committee (PDAC) will review data supporting their new drug application (NDA) for MDMA capsules, which are to be used in comb...

The pharmaceutical industry faces a patent cliff together in the years leading up to 2030. Learn what this means for drug pricing, their outsourcing partners, and drug innovation of the future. 

Two key players in the COVID-19 vaccine story – Pfizer/BioNTech and Moderna – have begun the latest chapter of their global legal battle over patents concerning technology for the development of mRNA therapeutics such as the COVID-19 vaccin...

CPHI North America will unite the pharmaceutical supply chain in Philadelphia from May 7–9, 2024 for 3 days of innovation and connections. As part of the content Agenda, our Diversity Track will bring the industry together to discuss the imperati...

China’s anti-espionage laws have caused concern among western pharmaceutical groups over potential arrests or denial of access for foreign inspectors in China-based facilities and manufacturing partners, posing a risk to the supply of drug produc...

This month’s CPHI Webinar Series explored achieving manufacturing excellence in pharma through the digitalisation of daily processes. Presented by Joe Doyle, Head of Sales at EviView, and Bikash Chatterjee, President and Chief Scientific Off...

The CPHI Milan Pharma Awards, which are now open for nominations until 18 May 2024, celebrate the innovators making a difference. This year, two new categories have been added to further honour the contributions of a diverse range of pharma professiona...

For the pharmaceutical industry, outsourcing drug development, manufacturing, and research operations to contract organisations is not just a passing trend – increasingly, the partnership between drug sponsor and drug vendor is one of vital impor...

Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. 

Dietmar Siemssen, CEO of German primary packaging manufacturer Gerresheimer, states that approximately 4% of the company’s revenue growth each year to come from deals with drugmakers of weight loss and diabetes products, particularly GLP-1 class ...

Researchers have created a new approach to the designing of eco-friendly nanofibres extracted from rice husks, addressing the critical need for sustainable packaging materials in food and biopharmaceutical products.  

In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...

Boston Scientific announced the FDA approval of their medical device AGENT Drug-Coated Balloon (DCB) for the indication of coronary in-stent restenosis in coronary artery disease patients.  

Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion.  

On February 20, 2024, CPHI Online hosted a webinar on Innovative Strategies for B2B Pharma Marketeers. Featuring expert speakers from across the pharmaceutical value chain, this webinar delves into how B2B pharma marketeers can create better content to...

Wegovy®, the weight loss drug from Novo Nordisk has been creating headlines since it’s early testing phases, through it’s approval in June 2021 by the US FDA and January 2022 from the European Medicines Agency, and it continues to do so...

In the last week, the US FDA has granted approval/accelerated approval to three different oncology drugs, each from different drugmakers with different indications. 

On February 5, 2024, Novo Holdings announced their intention to acquire pharma and biotech CDMO Catalent at US$16.5 billion. Read more about what this means for the pharmaceutical industry as a whole, from drugmakers to their partners in manufacturing....

In January 2024, Saudi Arabia released its National Biotech Strategy, an ambitious plan to localise biomanufacturing, incentivise R&D and establish the Kingdom as the regional biotech leader by 2030, and an internationally recognised hub by 2040. 

In this monthly series, we bring insightful content, events, and communities dedicated to sharing best practices for DE&I strategies and showcasing underrepresented voices in the pharmaceutical community. 

Novo Nordisk’s holding and investment parent company will acquire the publicly owned CDMO at the end of 2024, taking it private and selling three of its drug manufacturing facilities to Novo Nordisk. 

The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024.

The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024.

2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused...

The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. 

The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. 

Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations.

German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa.

In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. 

During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most. 

During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.  

Manufacturing for the diabetes and weight-loss drugs Ozempic and Wegovy is expected to increase with a billion-dollar investment Novo Nordisk production site located in Chartres, France.

At CPHI Barcelona (24–26 October, 2023), we spoke to Sireesha Yadlapalli, CEO of Pharmatech Associates, who gave a presentation on the implications of the US FDA’s Quality Management Maturity (QMM) Initiative, and spoke on the panel of the ...

Our Innovator Interviews takes a look at the cutting-edge strategies and technologies being implemented within the pharmaceutical supply chain through an in-depth discussion with a leading innovator in the industry. 

In our packed out content sessions at CPHI Barcelona this year we focus on some of the hottest topics coming up in the pharma industry, with each track sponsored by a leading expert in the field. 

In our packed out content sessions at CPHI Barcelona this year we focus on some of the hottest topics coming up in the pharma industry, with each track sponsored by a leading expert in the field. 

A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test.

To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development.

Injectable weight-loss treatments are prompting contract manufacturers to invest and include fill-finish services into their service portfolios, in a bid to attract pharmaceutical giants developing drugs similar to Novo Nordisk's Wegovy.

Pharmaceutical collaborations are nothing new to the industry. Increasingly complex drug development programs, calls for supply chain resiliency, and the involvement of all key stakeholders throughout a drug’s development lifecycle are pushing co...

Global market for mRNA-based oncology therapeutics expected to reach USD $2 billion by 2029, with promising results for the combination of mRNA candidates with immune checkpoint inhibitors to treat solid tumours.

Ardena and RiboPro have formed an alliance to boost their respective skills in manufacturing and producing nanoparticle and mRNA-based therapeutics to improve accessibility to this technology in the biotherapeutic landscape. 

Samsung Biologics agrees to use their biocampus Plant 4 for the manufacture of a line of products from Pfizer. 

Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre...

Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients.

The latest soft capsule technology from Roquette using modified pea starch as an alternative to gelatin. 

Download your FREE pharma marketing eBook to learn why it is so important for pharmaceutical marketeers to develop their digital content marketing strategies in order to establish their companies as thought leaders and industry experts. 

Novavax, developers behind the Matrix-M adjuvant, have entered into an agreement with the Bill and Melinda Gates Medical Research Institute to provide the adjuvant in preclinical vaccine research.

The collaboration between the pharmaceutical giant and scientific technology provider will aim to bring rapid and localised services to areas around the globe that lack affordable advanced genomic testing for breast and lung cancer.

As we prepare for CPHI North America from April 25–27 in Philadelphia, USA, CPHI Online caught up with some of the track sponsors to discuss how the show connects vital players within the North American pharmaceutical landscape.   ...

Merck and XtalPi Inc. collaborate on an AI-powered technology platform to predict the crystal morphologies of diabetic medication metformin HCl, validated by wet-lab experiments conducted with Merck’s expertise, in a ‘digital-first’ a...

Discover how the pharmaceutical workforce has evolved past the pandemic, and the challenges faced by the pharma industry during a talent acquisition and retention crisis. 

NextPharma has completed their acquisition of a Norway-based manufacturing site, specialising in chewable tablet technologies for calcium/vitamin D3 from pharmaceutical giant Takeda.

GSK has signed licensed agreements with three companies to manufacture generic versions of its preventative HIV medicine for distribution in lower-income countries but calls for increased transparency is putting pressure on the drugmaker. 

In collaboration with Thermo Fisher Scientific, UCSF has opened a new manufacturing site aimed at accelerating advanced cell and gene therapies for cancer, rare diseases, and other illnesses.

What does the rise of AI-powered chatbots such as ChatGPT and GPT-4 mean for pharma marketeers? 

The Pharma industry is expected to reach $1.9Tn in revenue by 2027, increasing at a rate of 3-6% per year, according to IQVIA1, with some regions being driven by volume, and others by innovation. Growth in developed economies is projected to be slow, w...

An agreement signed between TricorBraun and BioBottles will give nutraceutical companies (and potentially pharmaceutical companies) in the US and Canada access to the industry’s first fully biodegradable packaging option.

Vetter (Ravensbury, Germany), the aseptic filling and packaging CDMO has signed up to the UN Global Compact Network. 

In an effort to protect against potential future global health emergencies, the government of the UK and Moderna have cemented a 10-year partnership for vaccine manufacturing and research.

Capsules encompass one of the most popular solid oral dosage forms for pharmaceutical products, with the global empty capsule market predicted to rise to USD $3.7 billion by 2026. The growth in the capsule market can be partly attributed to the many op...

This year at Pharmapack 2023, we interviewed several leading women in the pharmaceutical industry about what it means to be a woman working in pharma. In the lead-up to International Women’s Day on March 8, 2023, CPHI Online is proud to highlight...

West Pharmaceutical Services, Inc. speaks to CPHI Online about celebrating their 100-year anniversary as an industry leader, and how they plan to continue driving innovation after the challenges posed from global disruptions in the last few years.

As we continue to celebrate the contributions of women in the pharmaceutical field following International Day of Women and Girls in Science and in the lead up to International Women’s Day on March 8, 2023, we take a look at some of the historic ...

Three reasons why advancing gender equity in healthcare should be a priority for pharma 

Trodelvy, an antibody–drug conjugate with indications against certain types of cancer, has been approved by the US FDA for a third indication against pre-treated HR+/HER2- metastatic breast cancer.

An increasing number of drug development pipelines are turning towards the use of HPAPIs to target rare and ‘undruggable’ diseases. In this article, we talk to leading industry experts about how pharmaceutical manufacturers are adapting and...

The Switzerland-based pharmaceutical process and ingredient developer and manufacturer announced the opening of their new sterile liquid drug product manufacturing facility in France.

With the Lunar New Year ushering in celebrations for the pharmaceutical community around the world on Sunday January 22, 2023, we’ve rounded up some of the top CPHI Online articles and reports from the last year looking at pharmaceutical markets ...

A new HPAPI development and manufacturing block is now open at Sai Life Sciences’ Bidar Manufacturing Campus, expanding the CRDMO’s capabilities in small molecule discovery and commercialisation.

A USD $42 million collaboration between AbbVie and Anima Biotech aims to leverage the latter’s mRNA Lightning technology platform to enhance therapeutic development programs in oncology and immunology.

Samsung Biologics has been awarded The Terra Carta Seal from the sustainable markets initiative.

A multi-year collaboration between BioNTech and the Government of the United Kingdom will see the expansion of the company’s presence in the UK, focusing on areas like cancer immunotherapies and infectious disease vaccines.

Machine-learning models demonstrate the potential to accelerate drug formulation discovery and development for long-acting injectables.

CordenPharma, the CDMO specialising in APIs, lipid excipients, and drug products, signs a new billion dollar contract to expand its manufacturing capabilities. 

Pharmaceutical company Moderna acquires genomics services company OriCiro Genomics, based in Tokyo, Japan, to boost mRNA therapeutics development and manufacturing portfolio.

Drugmakers such as Pfizer, GSK, BMS, AstraZeneca, and Sanofi are planning to raise prices for at least 350 unique drugs in the United States in early January.

Download our 2023 Pharma Trends Outlook report to discover the trends set to shape the pharmaceutical landscape in the new year, with expert opinions and insight from across the pharmaceutical value chain.

A comprehensive, long-term partnership agreement between AstraZeneca and G42 Healthcare is set to enhance local drug manufacturing in Abu Dhabi, UAE, and bolster pharmaceutical manufacturing innovation within the country.

The CDMO has joined the environmental initiative looking to align private sector companies with those aims upheld by the Paris Agreement to reduce global warming. 

AstraZeneca has recently announced that it will be acquiring the biotechnology company Neogene Therapeutics as part of it’s expansion into cell-based cancer treatments.